INTRODUCTION {#s1}
============

B-lineage acute lymphoblastic leukemia (B-ALL) represents 75-85% of all ALLs and is characterized by the accumulation of immature B cells, which results in the suppression of normal hematopoiesis. B-ALL is the most frequent cancer in children, with the highest incidence between 2 and 5 years, while it is relatively rare in adults, with a peak after the age of 50 \[[@R1]-[@R3]\]. While in childhood the survival rates are in the order of 80%, the outcome in adults is still unsatisfactory, with long-term survival rates of about 40-50% of cases \[[@R4]-[@R8]\]. An intermediate group is represented by the adolescents/young adults (AYA), who show an improved outcome when treated with pediatric-like protocols \[[@R9]-[@R11]\].

Besides the different prognosis, children and adults are characterized by a variable distribution of recurrent chromosomal aberrations with prognostic impact, such as high hyperdiploidy and *ETV6-RUNX1* transcript, common in children, *BCR-ABL1* and *MLL* rearrangements, more frequent in adults \[[@R3], [@R12]-[@R20]\]. While these lesions characterize about 50% of B-ALL, a considerable proportion of cases proves negative for gold-standard molecular screening (B-NEG ALL). The definition of the genetic landscape of this "genetically-orphan" subgroup has partially improved by the introduction of genome-wide technologies, such as gene expression profiling (GEP), single nucleotide polymorphism (SNP) arrays and next generation sequencing (NGS) \[[@R21]-[@R26]\]. The latter has clarified the molecular background of specific subgroups, such as "*BCR-ABL1*-like" and hypodiploid ALL, while a comprehensive description of B-NEG has so far not been provided \[[@R25]-[@R26]\].

We analyzed 168 B-NEG ALLs (50 children, 61 AYA, 57 adults) - distributed in a discovery panel (*N* = 13), screening panel 1 (*N* = 68) and screening panel 2 (*N* = 87) - by NGS and copy number aberration (CNA) analysis to refine the molecular scenario of B-NEG ALL cases and assess if different lesions might account for the different outcome between children, AYA and adults, with the ultimate goal of investigating the potential role of targeted therapeutic approaches.

RESULTS {#s2}
=======

Incidence and outcome of B-NEG ALLs stratified for age cohorts {#s2_1}
--------------------------------------------------------------

The meta-analysis of the incidence of known molecular aberrations in a cohort of over 5,000 ALL \[[@R3]\] revealed that within B-ALL, B-NEG cases represent 70.5% of childhood, 72.7% of AYA and 42.7% of adults. Furthermore, within the population included in the current study, we evaluated the outcome of the above mentioned age cohorts. Clinical outcome data were available for 142 patients (48 children, 50 AYA and 44 adults) with a median follow-up of 65 months. Overall survival (OS) was significantly different among children (83%), AYA (55%) and adults (29%), resembling that of ALL in general (Figure [1](#F1){ref-type="fig"}) \[[@R3]\].

![OS of B-NEG ALL patients, included in the present study, stratified for age cohorts](oncotarget-07-13886-g001){#F1}

Genomic overview of B-NEG ALL {#s2_2}
-----------------------------

Whole exome sequencing (WES) of the discovery panel cases revealed 136 mutated genes (10.5/case), with a similar load across the 3 age cohorts (Figure [2A](#F2){ref-type="fig"}). Mutated genes were highly heterogeneous across B-NEG ALL samples with only *FLT3*, *PREX2, PAX5* - recurrently mutated, being found in 2 of the 13 samples ([Table S1](#SD1){ref-type="supplementary-material"}). In spite of this, *in silico* analyses revealed a significant enrichment of the following gene categories: focal adhesion/ECM interaction, small GTPase mediated signal transduction, ion transport and protein kinase activity, as described in [Supplemental Material and Table S2](#SD1){ref-type="supplementary-material"}.

![Overall load of genetic lesions of B-NEG ALL\
**A.** Load of somatic mutations and CNAs across different age cohorts. **B.** CNAs distribution and type across different age cohorts.](oncotarget-07-13886-g002){#F2}

By SNP arrays we detected 119 CNAs (9.1 CNAs/sample, range 4-22). The load and type of CNAs was heterogeneous across the age cohorts. Indeed, whilst childhood ALLs were affected by 9.8 CNAs, adult ALLs carried 4.6 CNAs on average. AYA displayed an intermediate behavior, with 2/5 samples being genetically complex and 3 harboring a number of CNAs similar to the adult cohort (Figure [2A](#F2){ref-type="fig"}). Pediatric samples were mostly characterized by gains of entire chromosomes. Contrariwise, AYA and adult patients were mainly affected by losses of variable size, ranging from deletions of chromosome arms to single exons (Figure [2B](#F2){ref-type="fig"}). The most common minimally deleted regions were those encompassing known target genes \[[@R21], [@R22]\]. Indeed, the screening of these known targets confirmed that the most frequently deleted genes were *IKZF1* (41.4%), *CDKN2A* (36.9%), *PAX5* (25.5%) and *ETV6* (17.8%) (Figure [3A](#F3){ref-type="fig"}).

![Incidence of the most common deletions in B-NEG ALL\
**A.** Frequency of deletions targeting *IKZF1*, *CDKN2A*, *PAX5*, *ETV6*, *EBF1*, *BTG1*, *RB1*, *CRLF2* - and grouped in functional categories - in the whole population and in age cohorts. Asterisks indicate deletions with a statistically significant different incidence when comparing children and AYA or children and adults. **B.** Distribution of the abovementioned deletions in children, AYA and adult populations.](oncotarget-07-13886-g003){#F3}

Identification and screening of the recurrently mutated genes {#s2_3}
-------------------------------------------------------------

Given the low number of recurrently mutated genes detected in the discovery panel, WES was broadened to 68 additional B-NEG cases (screening panel 1) and the bioinformatic analysis focused on the genes mutated in the discovery panel and/or reported as affected by mutations or CNAs in published ALL series \[[@R25]-[@R29]\]. This approach yielded a shorter list of genes frequently targeted by mutations, which overall clustered in the RAS/RTK and JAK/STAT cascades, or affected B-lineage differentiation, and also highlighted intriguing differences amongst the age cohorts ([Table S3](#SD1){ref-type="supplementary-material"}).

To validate the latter findings we sequenced the most frequently mutated genes within the abovementioned pathways - namely *FLT3*, *KRAS*, *NRAS, IL7R*, *JAK2, CRLF2, JAK1* and *PAX5* - in 87 additional B-NEG ALLs (screening panel 2). The results described below refer to a total population of 168 cases (50 children, 61 AYA and 57 adults).

Age-related genetic lesions in B-NEG ALL {#s2_4}
----------------------------------------

### Genetic lesions of PAX5 {#s2_4_1}

Among the mutations of B-lineage development genes, those affecting *PAX5* were the most common, occurring in 20 patients (11.9%). Mutations clustered in the paired-box domain with roughly 50% being represented by the hotspot P80R ([Figure S1A](#SD1){ref-type="supplementary-material"}). The comparison among age groups highlighted a significant difference between the percentage of mutations detected in children and adults (2% *vs* 19.3%, *p* = 0.005, [Figure S1B](#SD1){ref-type="supplementary-material"}); AYA displayed an intermediate behavior, with mutations observed in 13.1% of cases.

By integrating the mutational with the CN status, we confirmed that *PAX5* lesions increase with age progression, being detected in 13.3% of children, 28.6% of AYA and 44.6% of adults: the difference was statistically significant between children and adults, as well as by combining AYA and adults (*p* = 0.001, *p* = 0.004, [Figure S1C](#SD1){ref-type="supplementary-material"}).

### Recurrent deletions of B-cell differentiation and cell-cycle genes {#s2_4_2}

Beside *PAX5* deletions, the screening of CNAs of selected genes involved in B-cell development (i.e. *IKZF1*, *EBF1*, *BTG1*) as well as the cell-cycle related genes (i.e. *CDKN2A/B* and *RB1*) revealed that deletions were significantly more frequent in AYA and adult patients than in children. Overall, B-cell development genes were deleted in 26.6% of pediatric, 64.3% of AYA and 66.1% of adult cases. Similarly, 15.5% of pediatric, 58.9% of AYA and 50% of adult patients harbored deletions targeting cell-cycle genes. In particular, these differences achieved a statistical significance for *IKZF1*, *BTG1* and *CDKN2A*, as detailed in Figure [3A](#F3){ref-type="fig"}.

As a result, these selected CNAs tended to accumulate with age, with 46.6% of children, 82.4% of AYA and 87.5% carrying at least one CNA (Figure [3B](#F3){ref-type="fig"}).

### Distribution and features of RAS/RTK pathway mutations {#s2_4_3}

Mutations of *FLT3*, *KRAS* and *NRAS*, grouped in the RAS/RTK pathway, were detected in 26.8% (45/168) of cases. In particular, *KRAS* was mutated in 11.3% (19/168) of cases, *NRAS* in 9.5% (16/168) and *FLT3* in 8.3% (14/168) (Figure [4A](#F4){ref-type="fig"}). The latter was prevalently mutated in adults (12.3%) and AYA (9.8%), while only 2% of children carried *FLT3* mutations (Figure [4A](#F4){ref-type="fig"}). This difference reached statistical significance when comparing adults *vs* children, as well as by combining AYA and adults (*p* = 0.046 and *p* = 0.043, [Figure S2A](#SD1){ref-type="supplementary-material"}). *FLT3* mutations mainly targeted the tyrosine kinase catalytic domain (TKD, 50%) or were represented by internal tandem duplications (ITD) in the juxtamembrane domain (36%) (Table [1](#T1){ref-type="table"}, [Figure S2B](#SD1){ref-type="supplementary-material"}).

*KRAS* and *NRAS* mutations accumulated mostly in childhood: in fact, collectively *RAS* mutations were detected in 30% of children and in 14.7% of AYA and 14% of adults (*p* = 0.052, *p* = 0.045).

Mutations targeted almost exclusively (92%) the known hotspot G12 and G13, and in the remaining cases the aminoacidic residues 60-63 (Table [1](#T1){ref-type="table"}, [Figure S3](#SD1){ref-type="supplementary-material"}).

Finally, we found no overlap between *FLT3* mutations and *NRAS*, *KRAS* G12-13 mutations; nonetheless, 1 sample carrying a *FLT3* ITD and *KRAS* G60D mutations was detected. Moreover, 3 cases harbored both *NRAS* and *KRAS* mutations. Notably, concomitant *NRAS* and *KRAS* mutations were only observed in AYA and children.

Of interest, cytogenetic analyses - successful in 109/168 cases - revealed a hyperdiploid karyotype in 17, with only 5 of them harboring RAS/RTK mutations. Given the known association between hyperdiploidy and RAS/RTK mutations \[[@R30]-[@R36]\], the analysis was repeated excluding hyperdiploid cases and samples lacking a cytogenetic evaluation, a similar incidence of RAS/RTK-mutated cases was observed: *KRAS/NRAS* mutations were detected in 32% of children, 15.6% of AYA and 15.3% of adults, while *FLT3* mutations were detected in 12.5% of AYA and 15.3% of adults.

###### Features of the mutations affecting RAS/RTK pathway

  ID         Age   Cohort     Panel         Gene     Exon   AA change              Type of mutation    Domain (Uniprot)
  ---------- ----- ---------- ------------- -------- ------ ---------------------- ------------------- ------------------
  GQW_63     4     Children   Discovery     *FLT3*   20     M837-                  In frame deletion   TKD
  GQW_71     19    AYA        Discovery     *FLT3*   20     Y842N                  Missense            TKD
  GQW_220    16    AYA        Screening 1   *FLT3*   14     Y572C                  Missense            JM
  GQW_210    22    AYA        Screening 1   *FLT3*   14     ITD                    ITD                 JM
  GQW_222    23    AYA        Screening 1   *FLT3*   14     ITD                    ITD                 JM
  GQW_236    30    AYA        Screening 1   *FLT3*   16     N676K                  Missense            TKD
  ALL_132    20    AYA        Screening 2   *FLT3*   20     D835H                  Missense            TKD
  GQW_187    56    Adults     Screening 1   *FLT3*   14     ITD                    ITD                 JM
  GQW_199    59    Adults     Screening 1   *FLT3*   20     D835Y                  Missense            TKD
  GQW_230    39    Adults     Screening 1   *FLT3*   11     S446L                  Missense            Extracellular
  ALL_14     78    Adults     Screening 2   *FLT3*   14     ITD                    ITD                 JM
  ALL_19     40    Adults     Screening 2   *FLT3*   20     p.837_838delMSinsVQG   In frame indel      TKD
  ALL_104    65    Adults     Screening 2   *FLT3*   14     ITD                    ITD                 JM
  ALL_125    40    Adults     Screening 2   *FLT3*   21     P857S                  Missense            TKD
  GQW_249    12    Children   Screening 1   *KRAS*   2      G12D                   Missense            GTPase
  GQW_245    3     Children   Screening 1   *KRAS*   2      G13D                   Missense            GTPase
  GQW_248    9     Children   Screening 1   *KRAS*   2      G13D                   Missense            GTPase
  ALL_142    3     Children   Screening 2   *KRAS*   2      G13D                   Missense            GTPase
  WB_6\_PD   3     Children   Screening 2   *KRAS*   2      G12D                   Missense            GTPase
  WB_8\_PD   1     Children   Screening 2   *KRAS*   2      G12R                   Missense            GTPase
  WB_10_PD   3     Children   Screening 2   *KRAS*   2      G12S                   Missense            GTPase
  WB_11_PD   14    Children   Screening 2   *KRAS*   2      G12D                   Missense            GTPase
  WB_14_PD   5     Children   Screening 2   *KRAS*   2      G12D                   Missense            GTPase
  GQW_208    19    AYA        Screening 1   *KRAS*   3      E63K                   Missense            GTPase
  GQW_210    22    AYA        Screening 1   *KRAS*   3      G60D                   Missense            GTPase
  GQW_221    16    AYA        Screening 1   *KRAS*   2      G12D                   Missense            GTPase
  GQW_225    28    AYA        Screening 1   *KRAS*   2      G12D                   Missense            GTPase
  ALL_138    21    AYA        Screening 2   *KRAS*   2      G12V                   Missense            GTPase
  ALL_106    20    AYA        Screening 2   *KRAS*   2      G12D                   Missense            GTPase
  GQW_81     53    Adults     Discovery     *KRAS*   4      A146T                  Missense            GTPase
  GQW_196    58    Adults     Screening 1   *KRAS*   2      G12S                   Missense            GTPase
  ALL_91     48    Adults     Screening 2   *KRAS*   2      G13D                   Missense            GTPase
  ALL_120    47    Adults     Screening 2   *KRAS*   2      G12V                   Missense            GTPase
  GQW_247    2     Children   Screening 1   *NRAS*   2      G12A                   Missense            GTPase
  GQW_242    14    Children   Screening 1   *NRAS*   2      G13D                   Missense            GTPase
  GQW_254    9     Children   Screening 1   *NRAS*   2      G13D                   Missense            GTPase
  ALL_111    9     Children   Screening 2   *NRAS*   2      G13D                   Missense            GTPase
  ALL_146    14    Children   Screening 2   *NRAS*   3      Q61R                   Missense            GTPase
  WB_2\_PD   11    Children   Screening 2   *NRAS*   2      G13D                   Missense            GTPase
  WB_6\_PD   3     Children   Screening 2   *NRAS*   2      G12S                   Missense            GTPase
  WB_14_PD   5     Children   Screening 2   *NRAS*   2      G13D                   Missense            GTPase
  GQW_225    28    AYA        Screening 1   *NRAS*   2      G13D                   Missense            GTPase
  GQW_229    30    AYA        Screening 1   *NRAS*   2      G12D                   Missense            GTPase
  ALL_88     23    AYA        Screening 2   *NRAS*   2      G12D                   Missense            GTPase
  ALL_116    16    AYA        Screening 2   *NRAS*   2      G12D                   Missense            GTPase
  GQW_181    44    Adults     Screening 1   *NRAS*   2      G12A                   Missense            GTPase
  GQW_198    42    Adults     Screening 1   *NRAS*   2      G13D                   Missense            GTPase
  ALL_29     42    Adults     Screening 2   *NRAS*   2      G12S                   Missense            GTPase
  ALL_134    78    Adults     Screening 2   *NRAS*   2      G12D                   Missense            GTPase

### Distribution and features of JAK/STAT pathway mutations {#s2_4_4}

Mutations in genes converging into the JAK/STAT pathway - *JAK2*, *IL7R*, *CRLF2* and *JAK1 -* accounted for 12.5% of cases (21/168). Missense mutations targeting arginine 863 of *JAK2* and indels in exon 6 of *IL7R* were the most frequent, detected in 5.3% and 4.8% of cases, respectively. Less than 2% of cases harbored *CRLF2* F232C mutations (*N* = 3) or *JAK1* mutations (*N* = 2) (Table [2](#T2){ref-type="table"}). JAK/STAT mutations were uniquely detected in patients \>15 years (*p* \< 0.001): none was in fact found in children, whereas 13% of AYA and 17.5% of adult patients were affected (Figure [4B](#F4){ref-type="fig"}). Furthermore, JAK/STAT mutations were associated with male gender (*p* = 0.01) and higher white blood cell (WBC) counts (90.6 *vs* 43.5 ×10^9^/L in mutated *vs* WT cases, *p* = 0.002). GEP analysis of JAK/STAT-mutated samples, revealed that 10 of the 21 mutated samples (47.6%) displayed a *BCR-ABL1*-like profile, thus indicating that JAK/STAT mutations, though characterizing the *BCR-ABL1*-like cases, are not exclusive of this cohort ([Figure S4](#SD1){ref-type="supplementary-material"}).

Moreover, when analyzed in light of other features bearing a negative prognostic impact \[[@R23]-[@R25]\], 57.1% (12/21) carried an *IKZF1* deletion and 3 harbored also a *CRLF2-P2RY8* rearrangement ([Figure S4](#SD1){ref-type="supplementary-material"}). The latter aberration was overall detected in 5 (3 adults, 1 AYA and 1 child) out of 157 samples analyzed by MLPA.

Mutations targeting the JAK/STAT genes were mainly mutually exclusive, with only 1 sample carrying 2 mutations: one targeting *JAK2* and the other *CRLF2*, the latter detected at the subclonal level.

Moreover, only 4 cases displayed concomitant RAS/RTK and JAK/STAT pathway mutations: in 2 cases we found *IL7R* and *NRAS* mutations, in 1 sample *IL7R* and *KRAS* mutations, and, lastly, 1 case harbored *JAK1* and *KRAS* mutations (Figure [4C](#F4){ref-type="fig"}).

Contrariwise, *PAX5* mutations frequently overlapped with RAS/RTK (8/45) and JAK/STAT (7/21) mutations.

###### Features of the mutations affecting JAK/STAT pathway

  ID          Age   Cohort   Panel         Gene      Ex on   AA change                      Type of mutation    Domain (Uniprot)
  ----------- ----- -------- ------------- --------- ------- ------------------------------ ------------------- ------------------
  GQW_211     22    AYA      Screening 1   *JAK2*    16      I682F                          Missense            TK1
  GQW_239     19    AYA      Screening 1   *JAK2*    16      R683S                          Missense            TK1\^
  B-ALL_045   32    AYA      Screening 2   *JAK2*    16      R683S                          Missense            TK1
  B-ALL_092   16    AYA      Screening 2   *JAK2*    16      R683G                          Missense            TK1
  GQW_182     48    Adults   Screening 1   *JAK2*    16      R683G                          Missense            TK1
  GQW_235     37    Adults   Screening 1   *JAK2*    16      R683S                          Missense            TK1
  GQW_184     51    Adults   Screening 1   *JAK2*    16      R683G                          Missense            TK1\^
  GQW_185     49    Adults   Screening 1   *JAK2*    16      R683G                          Missense            TK1\^
  B-ALL_028   47    Adults   Screening 2   *JAK2*    16      R683S                          Missense            TK1
  GQW_255     31    AYA      Screening 1   *IL7R*    5       S185C                          Missense            Extracellular
  B-ALL_073   27    AYA      Screening 2   *IL7R*    6       LTIS -\> PRC (243..246)        Inframe indel       TM\^
  GQW_188     44    Adults   Screening 1   *IL7R*    5       S234N                          Missense            Extracellular
  GQW_181     44    Adults   Screening 1   *IL7R*    6       DPILLTIS -\> DRGC (239..246)   Inframe indel       TM
  GQW_186     66    Adults   Screening 1   *IL7R*    6       LLTI -\> C (242..245)          Inframe deletion    TM
  GQW_198     42    Adults   Screening 1   *IL7R*    6       LT -\> LMVKGSFNICG (244)       Inframe insertion   TM
  B-ALL_03    40    Adults   Screening 2   *IL7R*    6       ILLTIS -\> MC (241..246)       Inframe indel       TM\^
  B-ALL_013   48    Adults   Screening 2   *IL7R*    6       LTIS -\> QKGEC (243..246)      Inframe indel       TM
  B-ALL_07    31    AYA      Screening 2   *CRLF2*   6       F232C                          Missense            TM
  B-ALL_061   27    AYA      Screening 2   *CRLF2*   6       F232C                          Missense            TM\^
  B-ALL_028   47    Adults   Screening 2   *CRLF2*   6       F232C                          Missense            TM\^
  B-ALL_060   21    AYA      Screening 1   *JAK1*    14      A634D                          Missense            PK1
  GQW-195     43    Adults   Screening 1   *JAK1*    16      R724C                          Missense            PK1

![Incidence of RAS/RTK and JAK/STAT pathway mutations in B-NEG ALL\
**A.** Frequency of mutations targeting *KRAS*, *NRAS* and *FLT3*. **B.** Frequency of mutations targeting *JAK2*, *IL7R*, *CRLF2*, *JAK1*. **C.** Distribution of the mutations targeting the RAS/RTK pathway (light grey cells) and JAK/STAT signaling (dark grey cells).](oncotarget-07-13886-g004){#F4}

Outcome of B-NEG ALL stratified for age cohorts {#s2_5}
-----------------------------------------------

To assess whether the mutations identified had a role on patients\' outcome, we evaluated the impact on OS and DFS of RAS/RTK and JAK/STAT pathway mutations. Provided the relatively low incidence of the single gene mutations, clonal mutations (detected in \>20% of tumor population) were grouped into the JAK/STAT (*IL7R*, *JAK2*, *JAK1*, *CRLF2* mutations and *CRLF2*-rearrangements) and RAS/RTK (*FLT3*, *KRAS*, *NRAS*) pathways. Among the latter, only the most common hot-spot mutations - namely, ITD and D835 *FLT3* mutations and those targeting the G12-13 aminoacidic residues of *KRAS* and *NRAS* - were considered \[[@R37], [@R38]\]. When analyzing the impact of mutations targeting one pathway, samples harboring mutations of the other pathway were filtered out from the WT cohort.

Firstly, the entire B-NEG cohort - comprising children, AYA and adults - was analyzed and we observed that the RAS/RTK pathway mutations did not impact on long-term survival. At variance, the OS of JAK/STAT-mutated cases was significantly shorter than that of WT cases (29.4% *vs* 62.8% at 4 years; 95% CI 14.1-61.4 and 53.3-73.9, *p* = 0.003) (Figure [5A](#F5){ref-type="fig"}).

Samples carrying mutations in both pathways (*N* = 4) experienced the worse OS when compared to the samples harboring only JAK/STAT or RAS/RTK (*p* = 0.006); in fact, all the events occurred within 30 months (Figure [5B](#F5){ref-type="fig"}).

Given the diverse distribution of mutations and the heterogeneous treatments across age cohorts, we repeated these analyses by grouping AYA and adults, whose mutational profile and therapeutic regimens were comparable. This approach led to the results described below.

![Impact of JAK/STAT pathway mutations on B-NEG ALL patients\' outcome\
**A.** OS of JAK/STAT-mutated *vs* WT cases (analysis on the entire study population). **B.** OS of JAK/STAT-mutated *vs* RAS/RTK-mutated *vs* double mutant cases (analysis on the entire study population).](oncotarget-07-13886-g005){#F5}

### Impact of RAS/RTK pathway mutations on B-NEG ALL patients\' outcome {#s2_5_1}

Among the RAS/RTK pathway members, the mutations targeting *KRAS*/*NRAS* hotspot exerted the strongest effect on outcome. AYA and adult B-NEG ALL patients harboring *RAS* mutations displayed a shorter OS at 4 years than WT cases (11.4% *vs* 50%, CI 95% 1.8-70.8 and 37.8-66.2, *p* = 0.039) (Figure [6A](#F6){ref-type="fig"}). *RAS*-mutated cases had also a significantly shorter disease-free survival (DFS) (*p* = 0.006), being 0 at 4 years compared to 47.8% (95% CI 33.5-68.3) for WT cases (Figure [6B](#F6){ref-type="fig"}). On multivariate analysis, *RAS* mutations and age retained their significance on OS (*p* = 0.0171 and *p* = 0.0002, respectively) and DFS (*p* = 0.0458 and *p* = 0.0128, respectively).

Contrariwise, in the pediatric cohort the survival of RAS/RTK-mutated cases resembled that observed in WT cases.

![Impact of *RAS* mutations on the outcome of adults and AYA B-NEG ALL patients\
**A.** OS of *RAS*-mutated *vs* WT cases. **B.** DFS of *RAS*-mutated *vs* WT cases.](oncotarget-07-13886-g006){#F6}

### Impact of JAK/STAT mutations on B-NEG ALL patient\'s outcome {#s2_5_2}

The evaluation of the impact of JAK/STAT mutations on B-NEG ALL patient\'s outcome was confined to AYA and adult cases, since these mutations were absent in children. This analysis documented the negative impact of JAK/STAT mutations on the OS of adult patients only, with JAK/STAT-mutated cases having a 10% (95% CI 1.6-64.2) survival probability at 4 years, as opposed to 31.3% (95% CI 16.6-59.2) for WT patients (Figure [7A](#F7){ref-type="fig"}). JAK/STAT-mutated cases also had a DFS at 4 years of 16.7% (95% CI 2.8-99.7) compared to 46.9% (95% CI 25.6-86) for WT patients (*p* = 0.009, Figure [7B](#F7){ref-type="fig"}).

On multivariate analysis, JAK/STAT pathway mutations and WBC retained their significance on DFS (*p* = 0.0259 and *p* = 0.0273, respectively).

![Impact of JAK/STAT mutations on the outcome of adult B-NEG ALL patients\
**A.** OS of JAK/STAT-mutated *vs* WT. **B.** DFS of JAK/STAT-mutated *vs* WT cases.](oncotarget-07-13886-g007){#F7}

*In vitro* sensitivity assays show the efficacy of target specific inhibition {#s2_6}
-----------------------------------------------------------------------------

Finally, in order to examine the potential of targeting the RAS/RTK and JAK/STAT pathways in B-NEG ALLs, we performed *in vitro* sensitivity experiments by treating primary cells from cases harboring known mutations with gene or pathway specific inhibitors.

The FLT3 inhibitors quizartinib and crenolanib and the pan-TK inhibitor ponatinib (0.1 μM) were able to reduce the proliferation rate of primary B-NEG ALL cells from 3 patients carrying *FLT3* ITD mutations and 1 harboring a TKD mutation: indeed, after 72 hours of treatment, quizartinib reduced the percentage of proliferating cells to 28.3±9%, crenolanib to 29.5±21.1% and ponatinib to 20.7±7% (Figure [8A](#F8){ref-type="fig"}). Primary cells from 4 samples harboring *RAS* mutations - targeting the G12-13 hotspot - were sensitive to PI3K/mTOR inhibitors (0.1 μM): in particular, BEZ235 reduced the percentage of proliferating cells to 21.3±9% and rapamycin to 37.8±21.1%; in addition, cell proliferation decreased to 62.4±16.9% upon treatment with the MEK inhibitor selumetinib (0.1 μM) (Figure [8B](#F8){ref-type="fig"}). As expected, ruxolitinib and tofacitinib - not targeting FLT3 nor PI3K/mTOR or MEK signaling - proved ineffective in reducing the proliferation of *FLT3* as well as *KRAS/NRAS*-mutated primary cells.

When the sensitivity of primary cells carrying JAK/STAT pathway mutations was tested, ruxolitinib (0.1 μM) proved effective in reducing to 59% the proliferation rate of *JAK2*-mutated cells from 1 case and rapamycin (0.1 μM) reduced to 35.4% the proliferation of *IL7R*-mutated primary cells from another patient, in line with a downstream PI3K/mTOR cascade activation.

Beside their anti-proliferative activity, the above-mentioned drugs also exerted a pro-apoptotic effect, particularly evident for FLT3 inhibitors.

To assess whether the response to the selected inhibitors was specifically associated to the mutational status of B-ALL primary cells, we compared it with B-ALL cases that proved negative for *FLT3*, *KRAS* and *NRAS* mutations. The reduction of proliferation induced by crenolanib, quizartinib and ponatinib (0.1 μM) was significantly higher in *FLT3*-mutated than in *FLT3*-WT cases (*N* = 4, *p* = 0.002, *p* \< 0.0001, *p* = 0.0004, respectively) (Figure [8C](#F8){ref-type="fig"}). Similarly, the proliferation rate of *RAS*-mutated cases was considerably reduced in response to rapamycin and selumetinib (0.1 μM) when compared to *RAS*-WT B-ALL samples (*N* = 3, *p* = 0.024, *p* = 0.037) (Figure [8D](#F8){ref-type="fig"}). At variance, BEZ235, which simultaneously targets mTOR and PI3K, was also partly active in reducing the proliferation (50.5±21.4%, 0.1 μM) of *RAS*-WT primary cells.

![Target-specific inhibitors are effective in reducing B-NEG ALL primary cell proliferation\
**A.** Average values of ^3^H-thymidine incorporation of primary B-NEG ALL cells from 4 *FLT3*-mutated samples after 72 hours of treatment; crenolanib (0.1 μM) reduced the percentage of proliferating cells to 29.5±21.1%, quizartinib (0.1 μM) to 28.3±9.0% and ponatinib (0.1 μM) to 20.7±7.0%, on average. Compounds not targeting FLT3 (ruxolitinib and tofacitinib) proved ineffective. **B.** Average values of ^3^H-thymidine incorporation of primary B-NEG ALL cells from 4 samples carrying *KRAS* or *NRAS* mutations after 72 hours of treatment; BEZ235 (0.1 μM) reduced the percentage of proliferating cells to 21.3±9.0%, rapamycin (0.1 μM) to 37.8±21.1% and selumetinib to 62.4±16.9%, on average. Compounds not targeting PI3K/mTOR or MEK signaling (ruxolitinib and tofacitinib) proved ineffective. Each condition was run in triplicate. **C.** Average values of ^3^H-thymidine incorporation of primary B-NEG ALL cells from 4 *FLT3*-mutated and 4 *FLT3*-WT samples after 72 hours of treatment with crenolanib (0.1 μM). **D.** Average values of ^3^H-thymidine incorporation of primary B-NEG ALL cells from 4 *RAS*-mutated and 3 *RAS*-WT samples after 72 hours of treatment with rapamycin (0.1 μM).](oncotarget-07-13886-g008){#F8}

DISCUSSION {#s3}
==========

We describe the first in-depth genomic analysis of a broad cohort of B-ALLs lacking known fusion transcripts, including pediatric, AYA and adult cases. This "genetically orphan" subgroup deserves special attention, since it constitutes 70.5% of childhood, 72.7% of AYA and 42.7% of adult ALL cases \[[@R3]\], represents a suitable setting to identify additional lesions sustaining the heterogeneous clinical scenario between children and adults, and reflects the clinical outcome observed in ALL, where the worse prognosis is observed in adults.

By WES of the discovery panel we found that the load of somatic mutations in B-NEG ALL resembles what observed in other leukemias, being 10.5 per sample \[[@R26], [@R28], [@R39]\]. Since few recurrent mutations were detected, the study was broadened to two screening panels, for a total of 168 B-NEG ALL samples. This analysis, focused on the genes commonly altered in ALL, revealed an enrichment of mutations targeting genes involved in B-cell development and protein kinases signaling \[[@R25]-[@R29]\].

Among the B-cell development genes, *PAX5* mutations were the most common event - occurring in 19% of cases - and increased with age. When *PAX5* deletions were also considered, we observed the same pattern, with 44.6% of adults and only 13.3% of children carrying *PAX5* genetic lesions. Remarkably, similar differences were found when the analysis of CNAs was extended to other B-cell development genes and cell-cycle genes commonly affected by deletions in B-ALL that tend to accumulate with age. Taken together, these results indicate that the genetic background of children is considerably different from patients older than 15 years old.

When focusing on protein kinases cascades, we found that 26.8% of B-NEG ALL cases carry mutations in the RAS/RTK pathway. The deregulation of this pathway may be due to alterations of upstream signaling molecules, like the receptor tyrosine kinase FLT3, or of essential players of the pathway like NRAS and KRAS, as occurred in our series \[[@R37]\].

Within B-ALL, the role of *FLT3*, *KRAS* and *NRAS* mutations has been investigated mostly in the pediatric setting and has been linked to hyperdiploid, *MLL*-rearranged ALL, hypodiploid, as well as high-risk pediatric cases, as elucidated by NGS \[[@R26], [@R30]-[@R36]\]. Our findings encourage a thoughtful reconsideration of their role since we documented that *FLT3*, *KRAS* and *NRAS* mutations are also a common event in B-NEG ALL with a different distribution across age cohorts. In particular, *FLT3* mutations were specific of AYA and adults, while *NRAS* and *KRAS* alterations were prominent in children: in fact, in the latter cohort they collectively accounted for 30% of cases, consistent with the previously reported association with younger age at presentation \[[@R36]\]. Importantly, RAS/RTK mutations were not confined to hyperdiploid cases, as previously reported: in fact, in our cohort mutations were detected in both hyperdiploid and non-hyperdiploid cases.

The clinical impact of RAS/RTK pathway mutations has been explored with contradictory results and seems to be mainly subgroup-dependent. In fact, while several studies, including the largest analysis performed in pediatric cases \[[@R36]\], failed to document any significant effect of *RAS* mutations on survival, a recent paper focusing on *MLL*-rearranged infant ALL documented an independent prognostic factor of *NRAS/KRAS* \[[@R33], [@R35], [@R36]\]. Similarly, while the impact of *FLT3* mutations has been widely explored in acute myeloid leukemia \[[@R40]\], it is unclear whether *FLT3* mutations affect the outcome of ALL patients \[[@R26], [@R30], [@R31]\]. In our series, given the low number of mutations affecting each single gene we grouped them according to their pathway. When we evaluated the outcome of patients carrying RAS/RTK mutations, we observed a peculiar pattern: AYA and adult mutated cases - all enrolled in clinical trials for adults - had a significantly reduced OS and DFS when compared to WT patients, while the outcome of pediatric cases was not influenced by these mutations, in line with previous reports, most likely because of the effect of more aggressive regimens.

Overall, these results prompted us to investigate the efficacy of specific inhibitors, in light of their availability. Among the *FLT3* inhibitors, the newly introduced quizartinib and crenolanib are promising against ITD and D835 mutations \[[@R41]\]. In our *in vitro* assays, both compounds, as well as the third-generation pan-TKI ponatinib were effective in reducing the proliferation of *FLT3*-mutated primary cells.

Since RAS proteins have proven challenging to inhibit, an alternative strategy is to interfere with the RAS signaling at different levels of the pathway \[[@R42], [@R43]\]. Encouraging results have been obtained with the inhibitors of PI3K/mTOR and MEK1/2 \[[@R26], [@R44]\]. Consistently, in the current study, samples carrying *NRAS* or *KRAS* mutations proved highly sensitive to rapamycin and to the dual PI3K/mTOR inhibitor BEZ235; the proliferation rate was also inhibited by the MEK1/2 inhibitor selumetinib, though at a lower extent.

These findings qualify FLT3, PI3K/mTOR and MEK1/2 inhibitors as alternative therapeutic agents for B-NEG ALL patients, especially in adults/elderly who frequently suffer of comorbidities and often cannot undergo intensive chemotherapeutic approaches.

The other set of mutations that captured our attention were those leading to the JAK/STAT signaling activation, being druggable and frequently altered in other poor prognosis ALL subsets \[[@R23]-[@R25], [@R34], [@R45]-[@R47]\]. Overall, we detected JAK/STAT mutations in 12.5% of B-NEG cases and, importantly, only AYA and adults were affected, with an incidence of 14.7% and 21%, respectively. This skewed distribution of lesions might be ascribed to the characteristics of our study population: in fact, unlike previously published papers describing high-risk and *BCR-ABL1*-like pediatric ALL cases \[[@R23]-[@R25], [@R34], [@R45]-[@R47]\], our cohort was not chosen for unfavorable clinical features nor for a peculiar GEP, and included all age cohorts. Therefore, our data indicate that unselected pediatric B-ALLs are rarely affected by these mutations, whereas their incidence increases with age. We provide direct evidence that considering only the mutational status of JAK/STAT members, regardless of GEP and concomitant rearrangements, it is possible to single out adult B-NEG ALLs experiencing a worse OS and DFS. As a matter of fact, the cohort of JAK/STAT-mutated only partly overlap with the *BCR-ABL1*-like profile, thus indicating that the mutational characterization may integrate the identification of *BCR-ABL1*-like cases, presently not completely elucidated nor straightforward.

The identification of JAK/STAT lesions bears also important therapeutic implications given the possibility of interfering with JAK members or downstream pathways as shown by previous experimental models \[[@R42], [@R43], [@R48]\] and our pilot experiments on primary cells.

In conclusion, our study, that was carried out in B-ALL cases without major molecular rearrangements of all ages, implements the current knowledge on ALL. Firstly, we hereby show that the genetic background is significantly different between children, AYA and adults, with the number of deleterious lesions incrementing with age progression; this phenomenon might, at least in part, account for the different outcome between age cohorts. Second we show that RAS/RTK pathway mutations negatively impact on OS and DFS while they do not affect children\'s outcome. Along the same line, we show that JAK/STAT mutations confer a worse prognosis within the adult population. Finally, we show that by targeting these lesions we can reduce the *in vitro* leukemic cell proliferation, thus indicating that specific inhibitors might be integrated in the therapeutic backbone of ALL.

MATERIALS AND METHODS {#s4}
=====================

Experimental strategy {#s4_1}
---------------------

Bone marrow samples from 168 patients (median age: 23 years, range 1.2-78) with newly diagnosed B-ALL, containing \>70% of leukemic blasts and negative for recurrent fusion genes (*BCR-ABL1*, *ETV6-RUNX1*, *E2A-PBX1*, *MLL* rearrangements, defined B-NEG), were included in the present research. Three age cohorts were considered: 1-15 years (children, 50 patients); 16-35 years (AYA, 61 patients); \>36 years (adults, 57 patients). The study involved 3 phases ([Figure S5](#SD1){ref-type="supplementary-material"}): 1) WES and CNA analysis of 13 samples and their paired germline DNA (discovery panel, [Table S4](#SD1){ref-type="supplementary-material"}); 2) WES of 68 additional cases (screening panel 1, [Table S5](#SD1){ref-type="supplementary-material"}); 3) sequencing of selected genes by Sanger or NGS in 87 patients (screening panel 2, [Table S5](#SD1){ref-type="supplementary-material"}). Further details are provided in [Supplemental Material and Table S6](#SD1){ref-type="supplementary-material"}.

Sequencing analyses {#s4_2}
-------------------

Tumor and germline genomic DNA (gDNA, 3 μg) from the discovery panel patients and gDNA (1 μg) from the screening panel 1 tumor samples were enriched in protein coding sequences by the SureSelect Human All Exon 50Mb and the SureSelectXT2 Human All Exon kits, respectively (Agilent Technologies, Santa Clara, CA). Captured targets were subjected to massively parallel sequencing (HiSeq 2000 analyzer, Illumina, San Diego, CA) with the paired-end 2 × 100 bp read option ([Tables S7 and S8](#SD1){ref-type="supplementary-material"}).

Mapping to the hg19/NCBI GRCh37 and identification of tumor-specific variants of the discovery panel was performed as described \[[@R39], [@R49]\], while the analysis of screening panel 1 required more stringent criteria ([Supplemental Material](#SD1){ref-type="supplementary-material"}).

After validation by Sanger, frequently mutated genes (*PAX5*, *FLT3*, *KRAS*, *NRAS, JAK2, JAK1, IL7R, CRLF2*) were sequenced in the screening panel 2 by Sanger sequencing or NGS (Genome Sequencer Junior 454, Roche Applied Science®) ([Supplemental Material, Table S9](#SD1){ref-type="supplementary-material"}).

CNA and GEP analyses {#s4_3}
--------------------

CNA analysis of the discovery panel was performed with the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA; GSE67405) and processed as previously described \[[@R39]\]. Recurrent deletions and *CRLF2* rearrangements were screened by the Salsa MLPA P335-A3 ALL-IKZF1 kit (MRC-Holland, Amsterdam, the Netherlands) and analyzed as reported \[[@R50], [@R51]\].

GEP of B-NEG ALLs carrying JAK/STAT mutations was performed by using the HGU133 Plus 2.0 gene chips (Affymetrix) according to manufacturer\'s instructions and GEP analyses were carried out by dChip software (<http://www.hsph.harvard.edu/cli/complab/dchip/>). In order to recognize *BCR-ABL1*-like cases, gene expression levels of a set of genes specific of the *BCR-ABL1*-like profile, selected in the context of a previously described dataset \[[@R52]\], were evaluated in JAK/STAT-mutated cases.

Statistical analyses {#s4_4}
--------------------

Patients\' characteristics were compared by chi-squared or Fisher\'s exact test for categorical variables. Differences in distributions were assessed by Wilcoxon test for continuous data. OS and DFS curves were estimated by Kaplan-Meier product-limit method and compared using the log-rank test. Multivariate analysis was performed with Cox proportional hazards regression model to adjust the effect of *RAS* and JAK/STAT pathway mutations for WBC and platelets counts, hemoglobin levels, age and gender, on OS and DFS. All tests were 2-sided, accepting *p* \< 0.05 as index of statistical significance. All analyses relied on SAS v9.4 software.

*In vitro* assays {#s4_5}
-----------------

Annexin V/7AAD apoptotic test (BD Bioscience, San Josè, CA), MTT (TOX1 assay kit, Sigma Aldrich, St Louis, MO) and ^3^H-thymidine (Perkin Elmer, Waltham, MA) proliferation assays were performed to assess the sensitivity of primary B-NEG ALL cells carrying mutations of *FLT3*, *KRAS*, *NRAS*, *IL7R*, *JAK2* or WT for the same mutations to increasing doses (0.1-10 μM) of selected inhibitors (Selleck Chemicals Houston, TX) - of tyrosine kinases (ponatinib), *FLT3* (quizartinib, crenolanib), PI3K/mTOR/MEK pathway (rapamycin, BEZ235, selumetinib) and *JAK1/2* (tofacitinib, ruxolitinib). Drugs were added at time 0 and viability was measured after 48 and 72 hours. Cells were plated at 1×10^6^/ml and each condition was run in triplicate.
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